ORIC Pharmaceuticals, Inc.

NasdaqGS:ORIC 주식 보고서

시가총액: US$751.3m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ORIC Pharmaceuticals 관리

관리 기준 확인 4/4

ORIC Pharmaceuticals' CEO는 Jacob Chacko, May2018 에 임명되었습니다 의 임기는 6.08 년입니다. 총 연간 보상은 $ 3.15M, 18.9% 로 구성됩니다. 18.9% 급여 및 81.1% 보너스(회사 주식 및 옵션 포함). 는 $ 5.23M 가치에 해당하는 회사 주식의 1.08% 직접 소유합니다. 5.23M. 경영진과 이사회의 평균 재임 기간은 각각 5.1 년과 4.2 년입니다.

주요 정보

Jacob Chacko

최고 경영자

US$3.2m

총 보상

CEO 급여 비율18.9%
CEO 임기6.3yrs
CEO 소유권1.0%
경영진 평균 재임 기간5.3yrs
이사회 평균 재임 기간4.4yrs

최근 관리 업데이트

Recent updates

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

Aug 21
Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

ORIC Pharmaceuticals Stock: Too Early To Justify This Valuation

Jul 29

ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value

Jul 17

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

May 08
We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains

Mar 13

We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

Jan 18
We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Sep 27
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

Jun 14
ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

Jan 24
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech

Oct 14

Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?

Oct 08
Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?

ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09

Aug 11

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

Jun 24
ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

Mar 08
We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Nov 23
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Aug 05
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

ORIC Pharmaceuticals EPS beats by $0.04

May 06

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

Apr 16
Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

Jan 01
We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

Oric Pharma starts expansion phase of mid-stage solid tumor study with ORIC-101

Dec 21

Oric Pharma prices stock offering at $23

Nov 13

CEO 보상 분석

Jacob Chacko 의 보수는 ORIC Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$111m

Mar 31 2024n/an/a

-US$102m

Dec 31 2023US$3mUS$596k

-US$101m

Sep 30 2023n/an/a

-US$93m

Jun 30 2023n/an/a

-US$93m

Mar 31 2023n/an/a

-US$90m

Dec 31 2022US$4mUS$572k

-US$89m

Sep 30 2022n/an/a

-US$91m

Jun 30 2022n/an/a

-US$85m

Mar 31 2022n/an/a

-US$85m

Dec 31 2021US$7mUS$536k

-US$79m

Sep 30 2021n/an/a

-US$84m

Jun 30 2021n/an/a

-US$91m

Mar 31 2021n/an/a

-US$81m

Dec 31 2020US$6mUS$489k

-US$74m

Sep 30 2020n/an/a

-US$54m

Jun 30 2020n/an/a

-US$35m

Mar 31 2020n/an/a

-US$30m

Dec 31 2019US$672kUS$456k

-US$27m

Dec 31 2018US$2mUS$290k

-US$21m

보상 대 시장: Jacob 의 총 보상 ($USD 3.15M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 2.43M ).

보상과 수익: Jacob 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jacob Chacko (45 yo)

6.3yrs

테뉴어

US$3,153,083

보상

Dr. Jacob M. Chacko, M.D., MBA, has been Chief Executive Officer and Director of ORIC Pharmaceuticals, Inc. since May 2018 and has been its President since May 2019. Dr. Chacko joined the ORIC Pharmaceutic...

리더십 팀

이름위치테뉴어보상소유권
Richard Heyman
Co-Founder9.5yrsUS$186.87k0.32%
$ 2.4m
Jacob Chacko
President6.3yrsUS$3.15m1.03%
$ 7.8m
Dominic Piscitelli
Chief Financial Officer5yrsUS$1.45m0.12%
$ 892.6k
Pratik Multani
Chief Medical Officer6yrsUS$1.51m0.034%
$ 253.6k
Charles Sawyers
Co-Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Scott Lowe
Co-Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Lori Friedman
Chief Scientific Officer5.2yrs데이터 없음데이터 없음
Christian Kuhlen
General Counsel4.4yrs데이터 없음데이터 없음
Daniel Iazzetti
VP & Head of People2yrs데이터 없음데이터 없음
Edna Chow Maneval
Senior Vice President of Clinical Development5.5yrs데이터 없음데이터 없음
Matthew Panuwat
Chief Business Officer5.8yrs데이터 없음데이터 없음

5.3yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: ORIC 의 관리팀은 노련하고 경험 (평균 재직 기간 5.1 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Richard Heyman
Co-Founder9.5yrsUS$186.87k0.32%
$ 2.4m
Jacob Chacko
President6.3yrsUS$3.15m1.03%
$ 7.8m
Charles Sawyers
Co-Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Scott Lowe
Co-Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Laurence Lasky
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Angie You
Independent Director2.8yrsUS$140.37k0%
$ 0
Lori Kunkel
Independent Director4.3yrsUS$133.87k0.029%
$ 218.3k
Mardi Dier
Independent Director4.6yrsUS$147.87k0%
$ 0
Steven Hoerter
Independent Director3.1yrsUS$141.37k0%
$ 0

4.4yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 이사회: ORIC 의 이사회는 경험(평균 재직 기간 4.2 년)으로 간주됩니다.